The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects approximately 112 per 100,000 adults worldwide. It is more ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of $2.19bn in 2030.

US healthcare conglomerate Johnson & Johnson appears to have a promising IL-23-blocking oral peptide on its hands in the ...

The Champions Trophy has been once shared between two teams due to rain and no result. India and Sri Lanka were declared joint winners in 2002. But what happens if the 2025 Champions Trophy final ...

Reported global sales for key anti-IL brands (including Cosentyx, Taltz, Stelara, Tremfya, and Skyrizi) grew to ₹36 billion in 2024 from ₹13 billion in 2019, reflecting a 5-year CAGR of 22.9%.

The ESPN documentary series "The Last Dance" showed a younger generation of NBA fans that Michael Jordan is much more than a guy who sells retro sneakers. For those who witnessed Jordan's ...